Cannabidiol: A Promising Drug for Neurodegenerative Disorders?

被引:152
作者
Iuvone, Teresa [1 ]
Esposito, Giuseppe [2 ]
De Filippis, Daniele [1 ]
Scuderi, Caterina [2 ]
Steardo, Luca [2 ]
机构
[1] Univ Naples Federico II, Fac Pharm, Dept Expt Pharmacol, I-80131 Naples, Italy
[2] Univ Roma La Sapienza, Dept Physiol & Pharmacol V Erspamer, Rome, Italy
关键词
Alzheimer disease; Cannabinoid; Movement disorders; Multiple sclerosis; Parkinson disease; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TAU-PROTEIN HYPERPHOSPHORYLATION; CANNABINOID CB2 RECEPTORS; MULTIPLE-SCLEROSIS; IN-VIVO; ENDOCANNABINOID SYSTEM; OPEN-LABEL; NEUROPROTECTIVE ANTIOXIDANTS; ANTIINFLAMMATORY ACTIVITY; INDUCED NEUROTOXICITY;
D O I
10.1111/j.1755-5949.2008.00065.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neurodegenerative diseases represent, nowadays, one of the main causes of death in the industrialized country. They are characterized by a loss of neurons in particular regions of the nervous system. It is believed that this nerve cell loss underlies the subsequent decline in cognitive and motor function that patients experience in these diseases. A range of mutant genes and environmental toxins have been implicated in the cause of neurodegenerative disorders but the mechanism remains largely unknown. At present, inflammation, a common denominator among the diverse list of neurodegenerative diseases, has been implicated as a critical mechanism that is responsible for the progressive nature of neurodegeneration. Since, at present, there are few therapies for the wide range of neurodegenerative diseases, scientists are still in search of new therapeutic approaches to the problem. An early contribution of neuroprotective and antiinflammatory strategies for these disorders seems particularly desirable because isolated treatments cannot be effective. In this contest, marijuana derivatives have attracted special interest, although these compounds have always raised several practical and ethical problems for their potential abuse. Nevertheless, among Cannabis compounds, cannabidiol (CBD), which lacks any unwanted psychotropic effect, may represent a very promising agent with the highest prospect for therapeutic use.
引用
收藏
页码:65 / 75
页数:11
相关论文
共 100 条
[1]   Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice [J].
Bilsland, Lynsey G. ;
Dick, James R. T. ;
Pryce, Gareth ;
Petrosino, Stefania ;
Di Marzo, Vincenzo ;
Baker, David ;
Greensmith, Linda .
FASEB JOURNAL, 2006, 20 (07) :1003-+
[2]   Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide [J].
Bisogno, T ;
Hanus, L ;
De Petrocellis, L ;
Tchilibon, S ;
Ponde, DE ;
Brandi, I ;
Moriello, AS ;
Davis, JB ;
Mechoulam, R ;
Di Marzo, V .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (04) :845-852
[3]   An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis [J].
Brady, CM ;
DasGupta, R ;
Dalton, C ;
Wiseman, OJ ;
Berkley, KJ ;
Fowler, CJ .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) :425-433
[4]   Novel cannabinoid receptors [J].
Brown, A. J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (05) :567-575
[5]   Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis [J].
Cabranes, A ;
Venderova, K ;
de Lago, E ;
Fezza, F ;
Sánchez, A ;
Mestre, L ;
Valenti, M ;
García-Merino, A ;
Ramos, JA ;
Di Marzo, V ;
Fernández-Ruiz, J .
NEUROBIOLOGY OF DISEASE, 2005, 20 (02) :207-217
[6]   Cannabis for dyskinesia in Parkinson disease - A randomized double-blind crossover study [J].
Carroll, CB ;
Bain, PG ;
Teare, L ;
Liu, X ;
Joint, C ;
Wroath, C ;
Parkin, SG ;
Fox, P ;
Wright, D ;
Hobart, J ;
Zajicek, JP .
NEUROLOGY, 2004, 63 (07) :1245-1250
[7]   The endocannabinoid system in targeting inflammatory neurodegenerative diseases [J].
Centonze, Diego ;
Finazzi-Agro, Alessandro ;
Bernardi, Giorgio ;
Maccarrone, Mauro .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (04) :180-187
[8]   The window of therapeutic opportunity in multiple sclerosis [J].
Coles, AJ ;
Cox, A ;
Le Page, E ;
Jones, J ;
Trip, SA ;
Deans, J ;
Seaman, S ;
Miller, DH ;
Hale, G ;
Waldmann, H ;
Compston, DA .
JOURNAL OF NEUROLOGY, 2006, 253 (01) :98-108
[9]   Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis [J].
Collin, C. ;
Davies, P. ;
Mutiboko, I. K. ;
Ratcliffe, S. .
EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 (03) :290-296
[10]   Multiple sclerosis [J].
Compston, A ;
Coles, A .
LANCET, 2002, 359 (9313) :1221-1231